“We’re thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1 MMR achievement rate and encouraging safety/tolerability profile published in the recent ASH abstract. These data continue to reinforce our view of the potential of TERN-701 to become a best-in-disease treatment for patients with chronic myeloid leukemia,” said Amy Burroughs, chief executive officer of Terns Pharmaceuticals (TERN). “Our team continues to execute with precision and focus towards an updated and expanded CARDINAL readout at ASH, with an ultimate goal of bringing this important new therapy to CML patients.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
- H.C. Wainwright upgrades Terns on ‘compelling’ TERN-701 data
- Terns Pharmaceuticals price target raised to $27 from $14 at Barclays